Background: Kawasaki disease is a systemic vasculitis that affects small and medium-sized vessels, primarily the coronary arteries. First-line treatment includes intravenous immunoglobulin (IVIG) and acetylsalicylic acid; however, 20% do not respond adequately despite treatment. We describe a case treated with etanercept after initial IVIG failure, showing a good response. Case report: A 5-year-old female was diagnosed with classic Kawasaki disease. Echocardiography and angiotomography revealed giant and fusiform aneurysms in the coronary arteries. A first dose of IVIG therapy was administered without impro-vement; after the second dose, the fever persisted, so etanercept was administered, and the fever subsided. There were no new lesions in medium-caliber vessels and the previously identified coronary lesions did not progress. Conclusions: The use of etanercept in Kawasaki disease has demonstrated a clinically favorable response. Controlled clinical trials of this drug are needed to establish it as a formal therapy in cases of initial IVIG failure.
CITATION STYLE
Marriaga-Núñez, B., Arellano-Valdez, A., Abarca-De la Paz, J. P., Bonal-Pérez, M. A., Montaño-Durón, J. G., & Solórzano-Santos, F. (2023). Immunoglobulin-resistant Kawasaki disease. Boletin Medico Del Hospital Infantil de Mexico, 80(4), 260–264. https://doi.org/10.24875/BMHIM.23000078
Mendeley helps you to discover research relevant for your work.